Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2013
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 studyP L Zinzani, J M Vose, M S Czuczman, et al.
Digestive Diseases and Sciences|July 1, 1990
[14C]urea breath test for diagnosis of Helicobacter pyloriJ E Ormand, N J Talley, H A Carpenter, et al.
Leukemia|August 2, 2001
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemiaA Tefferi, C Y Li, C B Reeder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphomaT E Witzig, J M Vose, P L Zinzani, et al.
Leukemia|December 8, 2010
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaT E Witzig, C B Reeder, B R LaPlant, et al.
Leukemia|August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaT E Witzig, K M Laumann, M Q Lacy, et al.
Leukemia|July 2, 2011
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I studyG S Nowakowski, B LaPlant, T M Habermann, et al.
Leukemia|February 20, 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialC B Reeder, D E Reece, V Kukreti, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Pageof 3